FDA Clears HeartSciences' MyoVista wavECG Device, But No AI Algorithm Yet
HSCS has more than doubled off its 52-week low of $1.63 on elevated volume (15× avg).
Summary
HeartSciences received FDA 510(k) clearance for its MyoVista wavECG device as a 12-lead resting electrocardiograph for adult and pediatric patients. The clearance does not include the AI-ECG algorithm, and the company explicitly states it will not commercialize the device without a cleared AI algorithm and has no timeline for doing so. This is a regulatory milestone that validates the hardware but leaves the core AI value proposition unresolved. The company's financial position remains precarious—cash nearly depleted, negative equity, and a pending Nasdaq delisting—so this clearance may help the device's asset value in the ongoing Fortitude merger, but it does not change near-term revenue prospects. The merger with Fortitude is expected to close in Q4 2026, subject to shareholder approval.
Updates
· SEC 8-K — The 8-K attaches the press release and notes the clearance covers ECG signal acquisition and interpretation for adult and pediatric patients, with interpretive statements provided on an advisory basis.
At the time of this announcement, HSCS was trading at $3.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $21.1M. The 52-week trading range was $1.63 to $5.25. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.